Testing an oral medicine plus azacitidine to improve AML disease
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how a standard AML treatment plan affects a person’s disease status over time. It focuses on newly diagnosed adults who cannot safely get intensive chemotherapy, using oral venetoclax plus azacitidine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed acute myeloid leukemia (AML) confirmed by a bone or tissue test
- You have not had any prior treatment for AML
- You are not able to receive intensive chemotherapy (because of age 75+ or other health problems in younger adults)
- You are starting venetoclax plus azacitidine exactly as directed in the Colombia treatment plan
- You have not yet completed the first 28-day treatment cycle
- You have not joined another treatment study in the last 30 days
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of oral venetoclax and injected azacitidine for adults who are newly diagnosed with acute myeloid leukemia (AML) and cannot have standard strong chemotherapy. The goal is to see how well this treatment works and what side effects it may cause.
This Phase 2 study tests whether the combination of azacitidine and venetoclax can help people with acute myeloid leukemia (AML) who can’t handle standard intensive chemotherapy, including some relapsed or refractory cases. It also involves extra optional-style lab testing on your leukemia (bio-banking and “-omics” profiling) to learn which drug sensitivities may matter.
This study looks at how a person’s leukemia “disease state” changes over time for adults with acute myeloid leukemia (AML) who cannot receive the strongest (“intensive”) chemotherapy. It tests using oral venetoclax as a first treatment option, which may help control the disease for people ineligible for intensive chemo.
This Phase 2 trial compares two treatment approaches for people newly diagnosed with a specific type of AML (bone marrow cancer) that has an NPM1 mutation: venetoclax plus azacitidine versus intensive (strong) chemotherapy. It aims to see which plan works better and is safer for “fit” patients.
This trial tests a new combination of venetoclax plus a chemotherapy regimen (called CACAG) against a standard chemotherapy regimen (3+7) for adults with newly diagnosed intermediate- or high-risk AML. The goal is to see if the new combination works better.
This trial studies whether adding venetoclax to either azacitidine or decitabine can treat acute myeloid leukemia (AML) when earlier “hypomethylating” treatment has stopped working. You might be a candidate if you’ve already tried azacitidine or decitabine for a related blood condition and it failed, and you meet the health-safety limits.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.